In this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in ...
The 2023 European Society of Hypertension (ESH) and 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines both emphasize proper blood pressure (BP) ...
In this episode, Clyde W. Yancy, MD, MSc, MACC, and Leslie L. Davis, NP, PhD, FACC, discuss the 2022 AHA/ACC/HFSA Guideline for the Management of HF and where to consider newer treatments with ...
Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...
The ACC has launched a new program, Transform HF Care: New Horizons in Treatment, to educate clinicians on the latest advances, medications and interventions emerging in heart failure (HF) management ...
A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...
The ACC has issued new guidance on practical approaches for arrhythmia monitoring after stroke, offering clinicians tailored strategies to improve post-stroke care by identifying and managing atrial ...
Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...
Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...
Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to new research published in JACC and simultaneously presented at AHA 2024. Among the highlights: ...
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
A liberal transfusion strategy following major vascular or general surgery did not significantly improve outcomes at 90 days post procedure in patients at high risk of a cardiac event when compared to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback